HCPLive Network

Research Points to Promising Target for Irritable Bowel Disorder Therapies

 
Researchers at Wake Forest Baptist Medical Center and colleagues have identified a potential target for more effective therapies for irritable bowel disease (IBD) – a subset of human bone marrow stromal cells (HBMSC) that can thrive in the intestine and potentially help restore tissue within the intestine.
 
According to a news release from Wake Forest Baptist Medical Center, senior researcher Graca Almeida-Porada, MD, PhD, professor of regenerative medicine at Wake Forest Baptist's Institute for Regenerative Medicine, and colleagues “used cell markers to identify a population of stem cells in human bone marrow with the highest potential to migrate to the intestine and thrive.” The cells express high levels of Ephrin type B receptor 2 (EphB2), which is “involved in tissue repair and wound closure.”
 
Almeida-Porada is quoted in the release as saying that his team “identified two populations of human cells that migrate to the intestine‑‑one involved in blood vessel formation and the other that can replenish intestinal cells and modulates inflammation,” and hopes that “a mixture of these cells could be used as an injectable therapy to treat IBD.”
 
For the study, the researchers transplanted the HBMSCs into fetal sheep. They reported that “most of the transplanted cells were positioned in the crypt area, replenishing the stem cells in the intestine” at 75 days post-transplantation.
 
Almeida-Porada said that this study could be significant because although previous animal studies have “shown that the transplantation of bone-marrow-derived cells can contribute to the regeneration of the gastrointestinal tract in IBD,” the studies involved only small numbers of successfully transplanted cells.
 
He said the goal of this study was “to identify populations of cells that naturally migrate to the intestine and have the intrinsic ability to restore tissue health.” As the current study looked only at the cells’ ability to migrate to and survive in a healthy intestine, future studies will need to investigate cells’ viability in an inflamed intestine.
 
The study results were reported in “EphB2 Isolates a Human Marrow Stromal Cell Subpopulation with Enhanced Ability to Contribute to the Resident Intestinal Cellular Pool,” published in The FASEB Journal (the Journal of the Federation of American Societies for Experimental Biology). The authors described these results as identifying “a marker for isolating and culturing an expandable subpopulation” of HBMSCs with “enhanced intestinal homing and contribution to the [intestinal stem cell] region.”
 

Further Reading
Patients who have IBD, even those who are in clinical remission, often exhibit symptoms consistent with IBS, which can complicate the assessment and management of IBD and lead to unnecessary interventions.
The UK’s National Institute for Health and Care Excellence has issued draft guidance advising physicians to use a fecal calprotectin test to help distinguish between IBS and more serious bowel disorders.
Recent studies suggest that combination therapy with infliximab and azathioprine is more effective than monotherapy in patients with newly diagnosed Crohn's disease, but patients with more established Crohn's disease do not derive any extra benefit from triple therapy with infliximab, methotrexate, and prednisone compared to double therapy with infliximab and prednisone.
Over the past 30 years in Denmark, mortality from ulcerative colitis has decreased, but mortality from Crohn's disease has remained persistently higher than the general population, according to research published in the January issue of Clinical Gastroenterology and Hepatology.
Isotretinoin, a treatment for severe acne, has been linked to inflammatory bowel disease (IBD) in some case reports and 1 study. To investigate whether isotretinoin can induce IBD, French researchers conducted a 2-year nationwide registry study.
Living in sunnier parts of the country appears to be associated with a reduced risk of developing inflammatory bowel disease (IBD), particularly after the age of 30, indicates a long-term prospective US-based study.
Patients with moderate-to-severe Crohn's disease refractory to tumor necrosis factor antagonists who receive ustekinumab induction therapy have a higher clinical response rate and, during maintenance therapy, achieve significantly higher response and remission rates compared to patients receiving placebo, according to a study published in the Oct. 18 issue of the New England Journal of Medicine.
More Reading